Management of Medullary Thyroid Cancer

• Autores: David Viola, Rossella Elisei
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 48, Nº. 1, 2019, págs. 285-301
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Medullary thyroid cancer (MTC) is rare but aggressive. It can be cured only if intrathyroid at diagnosis. MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC patients have distant metastases at diagnosis and, when progressing, systemic therapy with vandetanib or cabozantinib should be considered. Before starting this treatment, the possibility of using a local treatment should be evaluated to delay systemic therapy. A multidisciplinary team should care for these patients.